Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd.verified

BHVN

Price:

$50.04

Market Cap:

$5.05B

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amy...[Read more]

Industry

Biotechnology

IPO Date

2022-09-23

Stock Exchange

NYSE

Ticker

BHVN

The Enterprise Value as of November 2024 (TTM) for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is 4.84B

According to Biohaven Pharmaceutical Holding Company Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.84B. This represents a change of 63.00% compared to the average of 2.97B of the last 4 quarters.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Historical Enterprise Value (quarterly & annually)

How has BHVN Enterprise Value performed in the past?

The mean historical Enterprise Value of Biohaven Pharmaceutical Holding Company Ltd. over the last ten years is 2.01B. The current 4.84B Enterprise Value has changed 24.00% with respect to the historical average. Over the past ten years (40 quarters), BHVN's Enterprise Value was at its highest in in the December 2019 quarter at 2.64T. The Enterprise Value was at its lowest in in the December 2018 quarter at -146734000.00.

Quarterly (TTM)
Annual

Average

2.01B

Median

2.32B

Minimum

-146734000.00

Maximum

5.49B

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Biohaven Pharmaceutical Holding Company Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 533.18%

Maximum Annual Enterprise Value = 5.49B

Minimum Annual Increase = -1683.18%

Minimum Annual Enterprise Value = -146734000.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20232.83B533.18%
2022446.71M-91.86%
20215.49B68.57%
20203.26B40.13%
20192.32B-1683.18%
2018-146734000.0011.61%

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Average Enterprise Value

How has BHVN Enterprise Value performed in the past?

The current Enterprise Value of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

2.92B

5-year avg

2.87B

10-year avg

2.01B

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Enterprise Value vs. Peers

How is BHVN’s Enterprise Value compared to its peers?

Biohaven Pharmaceutical Holding Company Ltd.’s Enterprise Value is greater than Immunome, Inc. (606.74M), greater than Inhibrx Biosciences, Inc. (411.31K), greater than AgeX Therapeutics, Inc. (19.70M), greater than Icosavax, Inc. (713.87M), greater than Day One Biopharmaceuticals, Inc. (1.07B), greater than Terns Pharmaceuticals, Inc. (508.25M), greater than X4 Pharmaceuticals, Inc. (20.60M), greater than Inozyme Pharma, Inc. (308.76M), greater than Mereo BioPharma Group plc (535.33M), greater than Apellis Pharmaceuticals, Inc. (3.59B), less than Blueprint Medicines Corporation (6.13B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (316.21M), greater than Kymera Therapeutics, Inc. (3.03B), less than Revolution Medicines, Inc. (9.07B), greater than C4 Therapeutics, Inc. (462.75M), greater than Agios Pharmaceuticals, Inc. (2.36B), greater than Nurix Therapeutics, Inc. (1.70B),

Build a custom stock screener for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biohaven Pharmaceutical Holding Company Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Biohaven Pharmaceutical Holding Company Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Biohaven Pharmaceutical Holding Company Ltd.'s Enterprise Value?

What is the highest Enterprise Value for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?

What is the 3-year average Enterprise Value for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?

What is the 5-year average Enterprise Value for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?

How does the current Enterprise Value for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) compare to its historical average?